REG - BioVentix PLC - Director/PDMR Shareholding

BioventixAnnouncement

22/11/2024 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241122:nRSV3923Na&default-theme=true

RNS Number : 3923N  BioVentix PLC  22 November 2024

Bioventix plc

 

("Bioventix" or "the Company")

 

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that the Company was notified on 22 November
2024 that on 22 November 2024 Bruce Hiscock, Chief Financial Officer of the
Company, purchased a total of 24 ordinary shares of 5 pence each in the
Company ("Ordinary Shares"), at an average price of 3,822 pence per Ordinary
Share (the "Purchase"). The Ordinary Shares were purchased under a dividend
reinvestment plan ("DRIP").

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 1,113
Ordinary Shares, representing approximately 0.02 per cent. of the issued share
capital of the Company.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details.

 

 

For further information please contact:

 

 Bioventix plc                                              Tel: 01252 728 001

 Peter Harrison                 Chief Executive Officer

 Cavendish                                                  Tel: 020 7220 0500

 Geoff Nash / Abigail Kelly     Corporate Finance

 Nigel Birks / Harriet Ward     ECM

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 

 1     Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                           Bruce Hiscock
 2.    Reason for the Notification
 a)    Position/status                                                Chief Financial Officer
 b)    Initial notification/Amendment                                 Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                           Bioventix Plc
 b)    LEI                                                            213800225MHX7LZQY108
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument    Ordinary Shares of 5 pence each
       Identification code                                            GB00B4QVDF07
 b)    Nature of the transaction                                      Purchase of Ordinary Shares
 c)    Price(s) and volume(s)                                         24 Ordinary Shares

                                                                      3,822 pence
 d)    Aggregated information:                                        Purchase of 24 Ordinary Shares at 3,855 pence each

       ·     Aggregated volume

       ·     Price
 e)    Date of the transaction                                        22 November 2024
 f)    Place of the transaction                                       London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEASFAASLLFFA